IDEA-FAST is a five-year, large-scale IMI2-JU/H2020 project on identifying digital endpoints to assess fatigue, sleep and activities of daily living in neurodegenerative disorders and immune-mediated inflammatory diseases building on data from sensing devices an apps.
Visit the IDEA-FAST project website.
The IDEA-FAST project will propose technology to revolutionise clinical research around fatigue and sleep disturbances for people living with chronic diseases such as Parkinson’s and Huntington’s disease.
Aims and Motivation
Fatigue and sleep disturbances are some of the most common issues facing people living with chronic diseases, however current large-scale research in this area rely on self-reported or impractical methods of data collection.
Getting better and more reliable data around fatigue and sleep could go a long way in improving people’s daily lives.
IDEA-FAST will combine the use of low-cost and accessible technology, such as activity trackers and bed sensors, with more traditional methods of clinical and functional data collection.
These digital endpoints can provide a more detailed and reliable picture of the extent of fatigue and sleep disturbances, as well as of the development over time. They will help to reduce patient burden, improve efficiency and enable more rapid development of new treatments.
IDEA-FAST will also create a start-of-the-art bespoke data management platform that will be one of the largest of its kind, and which will serve as a pilot product for evaluating digital health data in Europe.
The €21m EU project brings together 47 partners from academia, health and industry, and aims to put Europe at the forefront of digital assessments, enabling growth in a significant new worldwide market sector
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853981. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and PARKINSON’S DISEASE SOCIETY OF THE UNITED KINGDOM LBG.